XtalPi Nominates First siRNA Preclinical Candidate for IgA Nephropathy After Nine Months

XtalPi nominated its first internally developed siRNA preclinical candidate for IgA nephropathy following a nine-month discovery program. The candidate achieved subnanomolar silencing potency, with IC50 values tens of times lower than two clinical-stage reference molecules under corresponding assay conditions. A single dose sustained target-protein suppression for months in nonhuman primates, outperforming reference molecules in activity and durability. Toxicology studies indicated a broad safety window for the candidate. The Kodexia AI platform jointly optimized sequence and chemistry, increasing molecular design efficiency nearly threefold versus conventional workflows. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief via (Ref. ID: 202610151138PR_NEWS_USPR_____CN73506) on October 15, 2026, and is solely responsible for the information contai